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Background: Theoptimalmanagementofpatientswith combined carotidandcoronaryarterydisease requiringcardiac surgery
is still unknown. Staged carotid endarterectomy and carotid artery stenting (CAS), each followed by coronary artery bypass
graft (CABG), areoptions frequently employed.However, for patientswith severe carotid arterydisease inurgent needofopen
cardiac revascularization, staged operationsmay not be themost appropriate alternative. The aim of this studywas to describe
our experience using a synchronous CAS-CABG method with minimal interprocedural time. We used this synchronous
combination of procedures in patients with combined carotid and coronary artery disease admitted for urgent CABG.
Methods: Patients with concomitant severe carotid and coronary artery disease scheduled for synchronous CAS and urgent
CABG between December 2006 and January 2010 were included in the study. All procedures were performed at a single
center: the Cardiovascular Foundation of Colombia, in Floridablanca, Santander, Colombia. The study cohort was
characterized according to demographic and clinical characteristics, which included degree of carotid stenosis, presence/
absence of preoperative neurological symptoms, and cardiac operative risk proﬁle. All patients underwent CAS under
embolic protection devices and then CABG within the next 2 hours. Patients received aspirin pre- and postprocedure but
were started on clopidogrel only after CABG. The primary end point of the study was the composite incidence rate of
myocardial infarction, stroke, and death 30 days after CAS-CABG.
Results: Fifteen patients with concomitant severe carotid and coronary artery disease underwent synchronous CAS-CABG.
Most patients (60%) were men, and mean (6 standard deviation) age was 65.2 (6 8.4) years. Most patients (93%) were
neurologically asymptomatic. The median (interquartile range) ejection fraction and logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE) for the cohort were 55% (36%-62%) and 9.7% (4.6%-14.8%), respectively. There
were no deaths, major strokes, minor strokes, or myocardial infarctions during the procedure or within 30 days of CAS-
CABG. One patient experienced neurological symptoms likely as a result of transient ischemic attack ipsilateral to the CAS
procedure. None of the patients required cardiac or carotid reinterventions, and there were no cases of postoperative
bleeding requiring reoperation.
Conclusions: Synchronous CAS-CABG, when CABG is performed within the 2 hours of the CAS procedure, may be
a viable alternative to the more generally accepted staged combination, particularly among patients for whom CABG
cannot be postponed. We hope that this strategy will be further evaluated in larger prospective studies and adequately
powered randomized clinical trials. (J Vasc Surg 2013;57:58S-63S.)Cerebrovascular accident, or stroke, is a well-recognized
complication of cardiac surgery. The incidence of periopera-
tive stroke after coronary artery bypass graft (CABG) proce-
dures has been reported to increase among patients with
concurrent severe carotid artery stenosis,1-4 and the staged
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://dx.doi.org/10.1016/j.jvs.2012.06.116with combined rates of postoperative stroke, myocardial
infarction (MI), and death in the range of 10% to12%, partic-
ularly among patients aged 75 years and older and thosewith
bilateral carotid stenosis.5 Carotid stenosis may, in fact, be
found in up to 62% of patients who are scheduled to receive
a CABG, although severe unilateral and bilateral carotid
stenosis occur in 10% and 2% of these patients, respectively.6
Severe carotid stenosis is also found in asmany as 30%of early
strokes occurring post-CABG.7
To lower perioperative neurological morbidity, patients
with severe carotid stenosis scheduled for cardiac surgery are
frequently advised to undergo prophylactic carotid revascu-
larization. In this setting, frequent indications for carotid in-
terventions include symptomatic neurological status (recent
history of stroke, amaurosis fugax, or transient ischemic
attack [TIA]), contralateral carotid artery occlusion, and
severe concomitant vertebral artery stenosis.8 The optimal
management of patients with combined carotid and coro-
nary artery disease requiring cardiac surgery is, however, still
unknown.1,9-11
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tional approach to treatment of carotid artery disease in
patients in need of CABG. Although this approach has
been helpful in reducing the incidence of post-CABG
stroke, carotid artery stenting (CAS) has emerged as a suit-
able and less invasive alternative for the treatment of
patients with combined coronary and carotid disease.12-16
Current evidence reveals that CAS may be an alternative
to CEA for the treatment of isolated carotid artery disease
in some standard- and high-surgical-risk patients, although
the individual outcomes of stroke, MI, and death may vary.
In addition, some studies suggest that CAS might be a safer
alternative to prophylactic CEA in patients in need of
CABG.12-20 Nevertheless, optimal timing of the two
procedures, that is, whether CAS and CABG should be
performed in a staged or synchronous fashion, remains
controversial.
For those patients with a clinical indication for coro-
nary artery revascularization during the index admission,
planning a staged CAS-CABG process with weeks between
procedures was not an option because of the necessity of
prompt coronary revascularization. Very little data exist in
the literature describing the outcomes of patients under-
going synchronous CAS with urgent CABG. We report
our experience employing synchronous CAS-CABG with
a minimal interprocedural time less than 2 hours in patients
with combined carotid and coronary artery disease
admitted for urgent CABG.METHODS
Patient population. All consecutive patients with
concomitant severe carotid and coronary artery disease
scheduled at our center, the Fundación Cardiovascular
de Colombia, for synchronous CAS and urgent CABG
between December 2006 and January 2010 were included.
Standard institutional eligibility criteria for CAS in patients
requiring CABG include common or internal carotid
stenosis greater than 50% in symptomatic patients and
greater than 80% in asymptomatic patients. Eligibility was
assessed by carotid duplex scanning and conﬁrmed with
intraoperative catheter angiography. All pre-CABG carotid
duplex scanning and clinical screening were performed by
a physician member of the Division of Vascular Surgery,
after which the patient was considered eligible for pre-
CABG stent placement. The degree of carotid artery
stenosis was assessed according to the North American
Symptomatic Endarterectomy Trial (NASCET) criteria.10
Patients were deemed ineligible for CAS if they had
femoral artery disease that precluded femoral artery access,
severe proximal carotid tortuosity, presence of thrombus
within the lesion, severe intracranial stenosis (greater than
that of the target vessel), long near-occlusive lesions (“string
sign” lesions), and major residual neurological deﬁcit from
a previous disabling ipsilateral hemispheric stroke. Some of
these patients underwent CEA instead of CAS, which was
a decision made by the patient’s attending vascular surgeon.
All patients underwent neurological evaluation onadmission, and patients with lateralizing neurological
symptoms attributable to the carotid territory or history of
stroke underwent a formal evaluation by neurology. Patients
were also considered symptomatic if they had a history of
TIA, stroke, or amaurosis fugax within 6 months prior to
admission. Indications for CABG were based on standard
American College of Cardiology/American Heart Associa-
tion guidelines.21 The study was reviewed and approved by
our institutional ethics committee.
The necessity for prompt CAS and CABG was deter-
mined by a team of interventional cardiologists, cardiovas-
cular surgeons, and peripheral vascular surgeons. It was
based on several factors that include European System for
Cardiac Operative Risk Evaluation (EuroSCORE) calcula-
tions, severity of symptoms and hemodynamic status,
anatomic severity of the disease, as well as sociodemo-
graphic conditions. For instance, staged procedures may
not be a feasible option for some patients in our region
because of limited resources and transportation.
Carotid stenting technique. To facilitate immediate
progression to CABG after stenting, all patients underwent
the procedure under general anesthesia. All patients
received aspirin prior to the procedure and postoperatively.
None of the patients received antiplatelet therapy with clo-
pidogrel before CAS. However, there were patients who
were on clopidogrel prior to admission, which did not re-
present a reason to delay their treatment. CAS procedures
were performed using a ﬁxed angiographic unit (INNOVA
2000S; General Electric, Waukesha, Wisc). Unfractionated
heparin intravenous (IV) bolus (100 U/kg) was given to
achieve a target activated clotting time of 250 to 300
seconds. Additional heparin was administered approxi-
mately every 30 minutes to maintain the ACT within this
range. Intracranial views were obtained during angiography
to determine complete circle of Willis anatomy and to rule
out arterial intracranial lesions. Distal protection devices
were used for cerebral embolic protection in all patients.
Deployment of an appropriately sized self-expanding stent
was followed by balloon postdilatation (5 mm) when
necessary. A bolus of intravenous atropine (0.5 mg) was
administered per institutional protocol to prevent brady-
cardia and hypotension. Ipsilateral carotid and intracranial
angiography was performed after stent deployment. Proce-
dural success was deﬁned as successful stent deployment
with residual diameter stenosis #30%.
After CAS and with the assistance of experienced he-
modynamic and surgical ward staff, all patients were imme-
diately transported to the catheterization laboratory next
door to the operating room where CABG was performed
according to standard practice. The transportation
between rooms did not exceed 15 minutes. Aspirin and
clopidogrel were started after CABG once the possibility
of major bleeding was ruled out, usually on postoperative
day 2.
End point deﬁnition. The primary end point of the
study was the composite incidence rate of MI, stroke,
and death 30 days after CAS-CABG. Stroke was deﬁned
as any focal acute neurological event lasting at least 24
Table I. Baseline demographic and clinical characteristics
of patients (n ¼ 15)a
Characteristic No. (%)
Age, years 65.2 (8.4)a
Female sex 6 (40.0%)
Neurological symptomatic status 1 (6.6%)
Comorbidities
Hypertension 13 (18.6%)
Diabetes mellitus 4 (26.6%)
Dyslipidemia 9 (60.0%)
Smoking 11 (73.3%)
Previous MI 4 (26.7%)
Congestive heart failure 1 (6.6%)
Unstable angina pectoris 11 (73.3%)
Previous percutaneous coronary intervention 2 (13.3%)
Previous CAS 2 (13.3%)
Renal failure 2 (13.3%)
Contralateral carotid artery stenosis
No stenosis 7 (46.6%)
Stenosis <50% 3 (20.0%)
Stenosis 50%-80% 5 (33.3%)
Stenosis >80% 0 (0%)
Contralateral carotid artery occlusion 0 (0%)
Ejection fraction
<35% 3 (20.0%)
35%-50% 4 (26.7%)
>50% 8 (53.3%)
Logistic cardiac EuroSCORE
<10% 9 (60.0%)
10%-20% 5 (33.3%)
>20% 1 (6.6%)
Body mass index, kg/m2 23.1 (3.7)a
CAS, Carotid artery stenting; EuroSCORE, European System for Cardiac
Operative Risk Evaluation; MI, myocardial infarction.
aMean (standard deviation).
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ischemic or hemorrhagic stroke. Stroke was classiﬁed as
major stroke if patients had new neurologic deﬁcits with
a modiﬁed Rankin score $3 (moderate to severe disability
that restricts or impairs lifestyle) lasting more than 7 days.
A minor stroke was deﬁned as a new neurological deﬁcit
with a Rankin score of#3 (slight or no signiﬁcant disability
in performing activities of daily living) resolving completely
within 7 days. TIA was deﬁned as a focal neurological
deﬁcit lasting less than 24 hours. Predicted operative
mortality from cardiac surgery was calculated using the
standard EuroSCORE.22 Our institution uses the Euro-
SCORE, a risk stratiﬁcation system for the prediction of
hospital mortality and the assessment of quality of care, as
a prognostic score for patients undergoing cardiovascular
surgical procedures.22
Neurological evaluations using the National Institutes
of Health Stroke Scale were performed at baseline, within
72 hours postprocedure and at the 30-day follow-up. If
any suspicion of a neurological event existed, a formal
neurological consultation was immediately obtained.
Statistical analysis. Continuous variables are described
as means and standard deviations (SD) for normally distri-
buted variables and as medians and interquartile ranges
(IQRs) for non-normally distributed variables. Categorical
variables are described as frequencies and percentages.
For this small series with an expected low rate of
adverse events, an a priori decision was made to perform
only descriptive statistics. The SAS 9.2 (SAS Institute,
Cary, NC) and MedCalc 11.1.1.0 (MedCalc Software,
Mariakerke, Belgium) software programs were used for
data analyses.RESULTS
A total of 15 patients with combined severe carotid and
coronary artery disease underwent synchronous CAS and
urgent CABG during the study period. All of the patients
had unilateral CAS procedures. Nine (60%) were per-
formed on the right internal carotid artery, and six (40%)
on the left internal carotid artery. Baseline characteristics
of the study cohort are described in Table I. Most patients
(60%) were men. Mean (SD) age was 65.2 (6 8.4) years,
and there were no octogenarians in the study cohort.
The patient cohort possessed a high prevalence of comor-
bidities, which included hypertension (86.6%), smoking
(73.3%), unstable angina pectoris (73.3%), and previous
MI (26.7%). All patients were thus high surgical risk for
CEA. Of note, none of the patients had a history of chronic
obstructive pulmonary disease or previous CEA procedure.
One of the patients was neurologically symptomatic, with
a left brachial monoparesis caused by stroke within the
previous 6 months. Another patient had a history of stroke
7 years prior to the hospitalization for CAS-CABG. Before
arriving at our hospital, 12 (80%) patients were on antipla-
telet treatment with aspirin and ﬁve (33.3%) were on clopi-
dogrel. In addition, 13 (86.6%) patients were on
cholesterol-lowering therapy with statins. Two patientshad a history of CAS in the contralateral carotid artery.
Although 53% of the patients had contralateral carotid
artery disease, the degree of stenosis in the contralateral
side was not >70% in any of the patients, and none of
them had contralateral carotid occlusion. The median
(IQR) ejection fraction and logistic EuroSCORE for the
cohort were 55% (36%-62%) and 9.7% (4.6%-14.8%),
respectively. Preoperative coronary angiography revealed
left main coronary disease in eight (53.3%), three-vessel
disease in seven (47%), and four-vessel disease in four
(26.7%) patients.
All of the CAS procedures were performed under cere-
bral embolic protection with ﬁlter devices. Spider (EV3,
Plymouth, Minn) was used in 40%, FilterWire (Boston
Scientiﬁc, Natick, Mass) in 26%, EmboShield (Abbott
Vascular, Santa Clara, Calif) in 20%, and EPI Filter Wire
(Boston Scientiﬁc) in 13% of the cases. All of the distal
protection devices were successfully deployed and posi-
tioned. The following carotid stent devices were used: Pro-
tege (EV3; 47% of patients), Wallstent (Boston Scientiﬁc;
47%), and Precise (Cordis, Miami, Fla; 6%). Technical
success was achieved in 100% of the CAS procedures.
In the present series, all patients immediately underwent
CABG within 2 hours of CAS. The median (IQR) number
of coronary vessels undergoing revascularization was 3
Table II. Thirty-day outcomes after synchronous CAS-
CABG (n ¼ 15)
Event No. (%)
Death 0 (0.0%)
Major stroke 0 (0.0%)
Minor stroke 0 (0.0%)
Death or any stroke 0 (0.0%)
TIA 1 (6.7%)
MI 0 (0.0%)
Acute renal failure 1 (6.7%)
Postoperative cardiac arrest 1 (6.7%)
Cerebral hypoxic encephalopathy 1 (6.7%)
Pneumonia 1 (6.7%)
Pleural effusion 3 (20.0%)
Postoperative blood transfusion 8 (53.3%)
CABG, Coronary artery bypass graft; CAS, carotid artery stenting; MI,
myocardial infarction; TIA, transient ischemic attack.
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bypass (off-pump) in 40% of the cases. The median (IQR)
time on bypass for patients undergoing on-pump CABG
was 117 (110-128) minutes, and median clamp time was
82 (68-100) minutes. Mean (SD) postoperative length of
stay in the intensive care unit was 4.3 (62.5) days, and
median (IQR) length of hospital stay was 9 (6-12) days.
Table II summarizes postprocedural event rates within
30 days of the synchronous CAS-CABG. There were no
deaths, major strokes, minor strokes, or MIs periprocedur-
ally or within 30 days post-CABG. Only one patient expe-
rienced a TIA episode ipsilateral to the CAS procedure.
The event occurred 24 hours post-CABG and was
described as paresis of the left upper limb lasting less than
1 hour. The stent was later determined to still be patent
by duplex sonography. One patient with a 30% preopera-
tive ejection fraction endured cardiac arrest 3 hours post-
CABG, resulting in hypoxic encephalopathy conﬁrmed by
magnetic resonance imaging and leading to eventual total
dependency. Another patient developed nonoliguric renal
failure with a creatinine level of 2.1 and eventual resolution
and discharge in the week following the procedure. The
patient did not require dialysis and recovered without any
other complications. None of the patients required cardiac
or carotid reinterventions. There were no cases of postop-
erative bleeding requiring reoperations. However, almost
all the patients (93%) received red blood cell transfusions
intraoperatively or within the ﬁrst 24 hours post-CABG.
The median (IQR) number of red blood cell units trans-
fused was 3 (2-6) for the whole cohort. Of note, the
number of red blood cell units received by patients taking
clopidogrel prior to admission was not signiﬁcantly higher
than that of patients who were not on this antiplatelet
medication (median [IQR], 2.0 [1.5-7.2] and 3.5 [2.0-
5.0] units, respectively; P [Mann-Whitney test] ¼ .76).
Aspirin was started at 2.2 6 2.9 (1-12) days and clopidog-
rel at 3.2 6 2.5 (1-11) days post-CABG.
Median (IQR) long-term follow-up time was 48 (31-
293) days. No strokes or MIs were captured during this
period. However, two deaths were identiﬁed, one 60days and the other 2 years post-CABG. The investigators
were not able to verify the cause of death in either of the
two patients.DISCUSSION
We report our experience with a series of patients with
combined severe coronary and carotid artery disease neces-
sitating carotid stenting with immediate open coronary
vascularization. Our study adds valuable information to
the scant literature on CAS performed during the same
hospitalization with minimal delay before CABG.4,23-25
In our series, the 30-day incidence of postoperative death,
stroke, and MI was 0%, suggesting that the synchronous
hybrid approach CAS-CABG is feasible and safe. Our
results are comparable to those of the few published studies
on synchronous CAS-CABG, which have reported 30-day
cumulative incidence rates of stroke, MI, and death in the
range of 0% to 6%.4,23-27
Most previous studies on synchronous CAS-CABG are
small case series. However, their results consistently suggest
that the outcomes of this combined treatment approach
may be superior to those of alternative management strate-
gies for concurrent carotid and coronary disease. Alternative
management options frequently employed include synchro-
nous CEA plus CABG, staged CEA-CABG, reverse-staged
CABG-CEA, synchronous CEA plus CABG off bypass, and
staged CAS followed by CABG. Current evidence reveals
that the cumulative risk of stroke and death and of any
stroke, death, or MI for any of those alternatives lies
between 6.1% to 9.1% and 5.0% to 11.5%, respectively.12
From currently available data, it is impossible to ascertain
whether the improved outcomes from the synchronous
management approach represent a true treatment effect or
are the result of bias and insufﬁcient power of the studies.
Recently, Illuminati et al28 published the results of
a randomized clinical trial that assessed the timing of CEA
in patients with severe asymptomatic unilateral carotid
stenosis undergoing CABG. This study supports our current
approach to the management of patients with combined
carotid and cardiac disease in that we always perform the
carotid intervention immediately before CABG. As sug-
gested by the authors, delayed staged CEA may not prove
to be a safe alternative because of the increased risk of
stroke. Whether CEA or CAS is used for the treatment of
patients undergoing CABG depends on experience and
preference. Only a randomized clinical trial could validate
if CAS or CEA is superior, but such a trial would be logis-
tically difﬁcult to perform and, to our knowledge, has not
been designed or developed.
Our group has adopted CAS as the method of choice
for carotid revascularization in high-risk patients because
of our experience and low rate of complications with this
procedure. Moreover, CAS may indeed be an excellent
option for patients at high risk of MI, that is, those who
need CABG, as long as stroke and death rates after the
procedure are maintained low and within the American
Heart Association guidelines.22
JOURNAL OF VASCULAR SURGERY
62S Barrera et al February Supplement 2013We can speculate that our improved outcomes are
explained by several theoretical advantages of the synchro-
nous CAS-CABG approach when compared with staged
revascularization. First, the synchronous approach provides
shorter procedure time with less surgical trauma when
compared with combined surgical revascularization. This
is particularly important in the cases of high-risk patients.
Second, by eliminating the time interval between CAS
and CABG, the risk of acute MI between the two proce-
dures is expected to signiﬁcantly decrease. This effect is
more evident when staged CAS-CABG is compared with
staged CEA-CABG. In fact, data from systematic reviews
demonstrate that the 30-day incidence of MI is 6.5% after
staged CEA-CABG and only 1.8% after staged CAS-
CABG.29,30 Furthermore, the results of the Carotid Revas-
cularization Endarterectomy Versus Stenting Trial revealed
a signiﬁcantly increased incidence of MI after CEA as
compared with CAS (1.1% vs 2.3%; P ¼ .03), highlighting
the inferiority of CEA as compared with CAS with respect
to acute coronary events, even in non-high-coronary-risk
populations.17 Although the risk of MI seems to be low
when the staged CAS-CABG approach is used, it is not
known if the beneﬁt after synchronous CAS-CABG is simi-
larly low, as the combined baroreceptor-mediated hemody-
namic effect of CAS and the inﬂammatory response to
CABG on perioperative coronary adverse events are still
to be determined.
Despite the potential advantages, the synchronous
CAS-CABG approach is not exempt from important limita-
tions. The need for perioperative antiplatelet therapy to
prevent in-stent thrombosis and stroke after CAS is of
the utmost concern. In addition to aspirin, current guide-
lines recommend preoperative use of clopidogrel either as
continuous therapy or as a loading dose at least a few hours
pre-CAS, continued at least 30 days postprocedure.31
When synchronous CAS-CABG is planned, several factors
need to be considered regarding the type of antiplatelet
therapy to be used. These include the potential increase
in risk of interprocedural complications by increasing the
delay between CAS and CABG until antiplatelet therapy
post-CAS is completed, the increased risk of bleeding
during or after CABG in patients on clopidogrel, and the
increased risk of stroke if CAS is performed without dual-
antiplatelet protection. In our series, 33% of the patients
were on clopidogrel before CAS-CABG, although none
of these patients received it as a premedication for CAS.
The rates of stroke, MI, and death did not differ between
patients undergoing CAS-CABG with and those under-
going CAS-CABG without preoperative antiplatelet
therapy. In addition, none of the patients on preoperative
clopidogrel experienced a reoperation because of bleeding,
and the number of perioperative blood transfusions did not
differ between the groups. Other studies on synchronous
CAS-CABG in which patients did not receive pretreatment
with clopidogrel have shown similar low rates of post-
operative stroke.23-26 Nevertheless, whether the beneﬁts
of synchronous CAS-CABG without pretreatment withdual-antiplatelet therapy outweigh the risk of periproce-
dural stroke remains to be determined.
Our study has some important limitations. First, it is
a single-center small case series without a control group.
Second, most patients in our study cohort were neu-
rologically asymptomatic, and most of them did not have
severe contralateral carotid artery stenosis. This might limit
the generalizability of our results and partially explain the
low rates of postoperative stroke observed in this series.
Furthermore, the mean follow-up of our study was 48
days, and more long-term follow-up would be helpful in
the data analysis. Finally, general anesthesia was used for
all CAS procedures, limiting our ability to assess the neuro-
logical function of patients during CAS and through the
short interval between CAS and CABG. Although we
were unable to detect any neurological event occurring
during this period, all of our patients were neurologically
intact after CAS-CABG.
CONCLUSIONS
In this series of patients with concomitant severe
carotid and coronary artery disease in need of urgent
open coronary revascularization, synchronous CAS-
CABG was performed without any periprocedural occur-
rences of stroke, MI, or death. These ﬁndings suggest
that synchronous CAS-CABG may be a viable alternative
to the more frequently used staged CEA-CABG or CAS-
CABG. This strategy should be further evaluated in larger
prospective studies and adequately powered randomized
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